| Dr Sirisha Manyam, DO | |
|
302 Kensington Ave, Flint, MI 48503-2044 | |
| (810) 762-8200 | |
| Not Available |
| Full Name | Dr Sirisha Manyam |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 302 Kensington Ave, Flint, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962795013 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 5101021081 (Michigan) | Primary |
| Entity Name | Genesee Hematology-oncology, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902977101 PECOS PAC ID: 1153451265 Enrollment ID: O20100616000923 |
News Archive
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.
Routine screening for type 2 diabetes in adults at low and moderate risk is not recommended, although it is recommended for people at high and very high risk of the disease, state new diabetes screening guidelines published in CMAJ.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
High blood pressure in middle age can lead to impaired cognition and is a potential risk factor for Alzheimer's disease, according to a statement from the American Heart Association co-authored by Loyola Medicine neurologist José Biller, MD.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sirisha Manyam, DO 302 Kensington Ave, Flint, MI 48503-2044 Ph: (810) 762-8200 | Dr Sirisha Manyam, DO 302 Kensington Ave, Flint, MI 48503-2044 Ph: (810) 762-8200 |
News Archive
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.
Routine screening for type 2 diabetes in adults at low and moderate risk is not recommended, although it is recommended for people at high and very high risk of the disease, state new diabetes screening guidelines published in CMAJ.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
High blood pressure in middle age can lead to impaired cognition and is a potential risk factor for Alzheimer's disease, according to a statement from the American Heart Association co-authored by Loyola Medicine neurologist José Biller, MD.
› Verified 3 days ago
Vidya Sagar Kollu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: G3230 Beecher Rd, Suite 2, Flint, MI 48532 Phone: 810-342-5800 Fax: 810-342-5810 | |
Dr. Mohamad Monir Khoulani, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5080 Villa Linde Pkwy, Unit 4, Flint, MI 48532 Phone: 810-720-5440 Fax: 810-720-4670 | |
Russell Diponio, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4444 W Bristol Rd Ste 150, Flint, MI 48507 Phone: 810-230-9500 Fax: 810-230-0169 | |
Muhammad Bakleh, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5040 Villa Linde Pkwy, Flint, MI 48532 Phone: 810-230-0788 | |
Dr. Haymanot Y Gebre, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: G3230 Beecher Rd Ste 2, Flint, MI 48532 Phone: 810-342-5800 Fax: 810-342-5810 | |
Dr. Donald J Hardman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3499 S Linden Rd Ste 2, Flint, MI 48507 Phone: 810-820-8121 Fax: 810-820-8335 | |
Hameem Changezi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5084 Villa Linde Pkwy, Suite 6, Flint, MI 48532 Phone: 810-600-3399 Fax: 810-600-3398 |